CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies

Ugo Testa, Elvira Pelosi, Arthur E Frankel

Research output: Contribution to journalReview article

86 Citations (Scopus)

Abstract

Recent studies indicate that abnormalities of the alpha-chain of the interleukin-3 receptor (IL-3RA or CD123) are frequently observed in some leukemic disorders and may contribute to the proliferative advantage of leukemic cells. This review analyzes the studies indicating that CD123 is overexpressed in various hematologic malignancies, including a part of acute myeloid and B-lymphoid leukemias, blastic plasmocytoid dendritic neoplasms (BPDCN) and hairy cell leukemia.Given the low/absent CD123 expression on normal hematopoietic stem cells, attempts have been made at preclinical first, and then at clinical level to target this receptor. Since the IL-3R is a membrane receptor there are two relatively simple means to target this molecule, either using its natural ligand or neutralizing monoclonal antibodies. Recent reports using a fusion molecule composed by human IL-3 coupled to a truncated diphteria toxin have shown promising antitumor activity in BPDCN and AML patients.

Original languageEnglish (US)
Article number4
JournalBiomarker Research
Volume2
Issue number1
DOIs
StatePublished - Feb 10 2014

Fingerprint

Biomarkers
Hematologic Neoplasms
Interleukin-3 Receptor alpha Subunit
Membranes
Lymphoid Leukemia
Hairy Cell Leukemia
Molecules
Interleukin-3
Hematopoietic Stem Cells
Neutralizing Antibodies
Stem cells
Neoplasms
Fusion reactions
Monoclonal Antibodies
Ligands
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. / Testa, Ugo; Pelosi, Elvira; Frankel, Arthur E.

In: Biomarker Research, Vol. 2, No. 1, 4, 10.02.2014.

Research output: Contribution to journalReview article

@article{1adf8a776d57498fbfec6b89fa6b9249,
title = "CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies",
abstract = "Recent studies indicate that abnormalities of the alpha-chain of the interleukin-3 receptor (IL-3RA or CD123) are frequently observed in some leukemic disorders and may contribute to the proliferative advantage of leukemic cells. This review analyzes the studies indicating that CD123 is overexpressed in various hematologic malignancies, including a part of acute myeloid and B-lymphoid leukemias, blastic plasmocytoid dendritic neoplasms (BPDCN) and hairy cell leukemia.Given the low/absent CD123 expression on normal hematopoietic stem cells, attempts have been made at preclinical first, and then at clinical level to target this receptor. Since the IL-3R is a membrane receptor there are two relatively simple means to target this molecule, either using its natural ligand or neutralizing monoclonal antibodies. Recent reports using a fusion molecule composed by human IL-3 coupled to a truncated diphteria toxin have shown promising antitumor activity in BPDCN and AML patients.",
author = "Ugo Testa and Elvira Pelosi and Frankel, {Arthur E}",
year = "2014",
month = "2",
day = "10",
doi = "10.1186/2050-7771-2-4",
language = "English (US)",
volume = "2",
journal = "Biomarker Research",
issn = "2050-7771",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies

AU - Testa, Ugo

AU - Pelosi, Elvira

AU - Frankel, Arthur E

PY - 2014/2/10

Y1 - 2014/2/10

N2 - Recent studies indicate that abnormalities of the alpha-chain of the interleukin-3 receptor (IL-3RA or CD123) are frequently observed in some leukemic disorders and may contribute to the proliferative advantage of leukemic cells. This review analyzes the studies indicating that CD123 is overexpressed in various hematologic malignancies, including a part of acute myeloid and B-lymphoid leukemias, blastic plasmocytoid dendritic neoplasms (BPDCN) and hairy cell leukemia.Given the low/absent CD123 expression on normal hematopoietic stem cells, attempts have been made at preclinical first, and then at clinical level to target this receptor. Since the IL-3R is a membrane receptor there are two relatively simple means to target this molecule, either using its natural ligand or neutralizing monoclonal antibodies. Recent reports using a fusion molecule composed by human IL-3 coupled to a truncated diphteria toxin have shown promising antitumor activity in BPDCN and AML patients.

AB - Recent studies indicate that abnormalities of the alpha-chain of the interleukin-3 receptor (IL-3RA or CD123) are frequently observed in some leukemic disorders and may contribute to the proliferative advantage of leukemic cells. This review analyzes the studies indicating that CD123 is overexpressed in various hematologic malignancies, including a part of acute myeloid and B-lymphoid leukemias, blastic plasmocytoid dendritic neoplasms (BPDCN) and hairy cell leukemia.Given the low/absent CD123 expression on normal hematopoietic stem cells, attempts have been made at preclinical first, and then at clinical level to target this receptor. Since the IL-3R is a membrane receptor there are two relatively simple means to target this molecule, either using its natural ligand or neutralizing monoclonal antibodies. Recent reports using a fusion molecule composed by human IL-3 coupled to a truncated diphteria toxin have shown promising antitumor activity in BPDCN and AML patients.

UR - http://www.scopus.com/inward/record.url?scp=84904460162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904460162&partnerID=8YFLogxK

U2 - 10.1186/2050-7771-2-4

DO - 10.1186/2050-7771-2-4

M3 - Review article

C2 - 24513123

AN - SCOPUS:84904460162

VL - 2

JO - Biomarker Research

JF - Biomarker Research

SN - 2050-7771

IS - 1

M1 - 4

ER -